Nuclear receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
== Preparation of platelet poor plasma == Within 1 hour of blood collection, centrifuge capped citrate (blue top) tube for 15 minutes Using a plastic transfer pipet, remove the top 3/4 of plasma and place it in a plastic centrifuge tube with cap. Centrifuge the plasma (in the plastic centrifuge tube) for another 15 minutes. Using a plastic transfer pipet, remove the top 3/4 into a plastic tube. Do not disturb the plasma in the bottom of the spun tube, where any residual platelets will be. Aliquots with visible red cells or hemolysis (pink plasma) are not acceptable. Freeze plasma immediately. Samples for most laboratory assays should be frozen within 4 hours of collection.
Following trial and conviction at Wood Green Crown Court, Patrick Simms is sentenced to nine years in prison for the rape of a 15-year-old girl he committed after meeting the girl at a leisure centre in Hackney in 1987. 22 July – Seb Dance, the Deputy Mayor of London, confirms that day travelcards will be phased out for travel within London. 23 July – Newcastle's Northern Pride is forced to end early after heavy rain makes the festival site unsafe. 24 July – The Metropolitan Police announce that radical preacher Anjem Choudary has been charged with three terror offences. 25 July – Data published by the Department for Levelling Up, Housing and Communities indicates the number of homeless people to be at a 25-year high, with 105,000 households in England living in temporary accommodation, a figure that includes 131,000 children. Data released by the Metropolitan Police indicates that a 13-week campaign by Just Stop Oil has cost the force £7.7m to police. 26 July – The Court of Appeal overturns the 2004 conviction of Andrew Malkinson, convicted of a 2003 rape in Salford on unreliable evidence. 27 July – The UK government confirms that COVID-19-era licencing rules in England allowing pubs to sell takeaway drinks will end on 30 September. 28 July – The High Court rules that the planned extension of London's Ultra Low Emission Zone is lawful after rejecting a legal challenge from five Conservative-led local authorities.
== Mechanism == ATPase (also called FoF1-ATP Synthase) is a charge-transferring complex that catalyzes ATP to perform ATP synthesis by moving ions through the membrane. The coupling of ATP hydrolysis and transport is a chemical reaction in which a fixed number of solute molecules are transported for each ATP molecule hydrolyzed; for the Na+/K+ exchanger, this is three Na+ ions out of the cell and two K+ ions inside per ATP molecule hydrolyzed. Transmembrane ATPases make use of ATP's chemical potential energy by performing mechanical work: they transport solutes in the opposite direction of their thermodynamically preferred direction of movement—that is, from the side of the membrane with low concentration to the side with high concentration. This process is referred to as active transport. For instance, inhibiting vesicular H+-ATPases would result in a rise in the pH within vesicles and a drop in the pH of the cytoplasm. All of the ATPases share a common basic structure. Each rotary ATPase is composed of two major components: Fo/A0/V0 and F1/A1/V1. They are connected by 1-3 stalks to maintain stability, control rotation, and prevent them from rotating in the other direction. One stalk is utilized to transmit torque. The number of peripheral stalks is dependent on the type of ATPase: F-ATPases have one, A-ATPases have two, and V-ATPases have three. The F1 catalytic domain is located on the N-side (negative-side) of the membrane and is involved in the synthesis and degradation of ATP and is involved in oxidative phosphorylation.
Sources: en.wikipedia.org
=== DNA chips === Early biochips were based on the idea of a DNA microarray, e.g., the GeneChip DNAarray from Affymetrix, which is a piece of glass, plastic or silicon substrate, on which pieces of DNA (probes) are affixed in a microscopic array. Similar to a DNA microarray, a protein array is a miniature array where a multitude of different capture agents, most frequently monoclonal antibodies, are deposited on a chip surface; they are used to determine the presence and/or amount of proteins in biological samples, e.g., blood. A drawback of DNA and protein arrays is that they are neither reconfigurable nor scalable after manufacture. Digital microfluidics has been described as a means for carrying out Digital PCR.
=== Role of eRF3 === There have been many hypotheses on the function of eRF3 in the termination complex. An early hypothesis was that eRF3 helped eRF1 bind to the stop codon since eRF3 was structurally similar to EF-TU, which is a GTPase that brings charged tRNA molecules to the aminoacyl site of the ribosome in prokaryotic cells. Other hypothesis focus on the effects of GTP hydrolysis, which is mediated by eRF3, on eRF1. The pre-hydrolyzed GTP configuration of the termination complex favors eRF1 binding to the stop codon and orientating eRF1 to the peptide tRNA. The post-hydrolyzed GDP configuration promotes the release of the complex and dissociation of the ribosome. Additional studies hypothesis that the hydrolysis of GTP due to eRF3 allows the catalytic site of eRF1 to enter the p-site of the ribosome thus promoting the release of the nascent polypeptide.
A mass spectrometer consists of 5 components: sample inlet, ion source (or ionizer), mass analyzer, detector, data system. Each component can be varied somewhat independently from the other components, and the full mass spectrometer itself can be included as a component in an analysis pipeline, allowing great flexibility. The sample inlet prepares the sample to be analyzed in a suitable state. The ion source takes samples from the sample inlet, converts a portion of the sample into a stream of ions, and outputs it to the mass analyzer. There is a wide variety of ionization techniques, depending on the phase (solid, liquid, gas) of the sample and the efficiency of various ionization mechanisms for the unknown species. An extraction system removes ions from the sample, which are then targeted into the mass analyzer. The mass analyzer takes an input stream of ions and separates ("analyzes") its constituent ions according to their m/z, the mass-to-charge ratio. The detector measures the value of an indicator quantity and thus provides data for calculating the abundances of each ion present. Some detectors also give spatial information, e.g., a multichannel plate.
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.